Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Muggia

Showing results (41-50 of 95) with videos related to

Pageof 10
Sort By:
The Oncologist|March 27, 2014
Squamous cell carcinoma of the oral cavity in a woman with a 9-year history of ovarian cancer: is exposure to pegylated liposomal Doxorubicin a factor?Giovanni Randon, M Ornella Nicoletto, Nicola Milite, et al.
Molecular Cancer Therapeutics|November 11, 2011
Bortezomib: understanding the mechanism of actionBilal Piperdi, Yi-He Ling, Leonard Liebes, et al.
The Oncologist|February 25, 2014
Continuous-infusion topotecan and erlotinib: a study in topotecan-pretreated ovarian cancer assessing shed collagen epitopes as a marker of invasivenessEiran Warner, Leonard Liebes, Benjamin Levinson, et al.
Breast Care (Basel, Switzerland)|November 7, 2018
Meeting Report: Hereditary Breast and Ovarian Cancer (HBOC): Risks and Challenges. September 10-12, 2009 Bari, ItalyAngelo Paradiso, Stefania Tommasi, Brunella Pilato, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancerHoward Hochster, Abraham Chachoua, James Speyer, et al.
Kidney International|January 2, 2014
Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancerLinda Shavit, Meyer D Lifschitz, Alberto Gabizon, et al.
Anticancer Research|March 9, 2012
Cisplatin with capecitabine: tolerance and activity in a phase I/II study preferentially enrolling patients with gastric cancerJennifer Wu, Theresa Ryan, Benjamin Levinson, et al.
Ecancermedicalscience|September 1, 2020
Endometrial adenocarcinoma presenting as a suprasellar mass: lessons to be learnedEvgenia Granina, Julia Fehniger, Douglas Kondziolka, et al.
Gynecologic Oncology Reports|October 21, 2020
Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinomaAndrey Moiseyenko, Franco Muggia, Thomas Condamine, et al.
Annals of Surgical Oncology|October 2, 2013
Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatinMaryann Kwa, Susan Edwards, Andrea Downey, et al.
Pageof 10

Showing results (41-50 of 95) with videos related to

Sort By:
Pageof 10
The Oncologist|March 27, 2014
Squamous cell carcinoma of the oral cavity in a woman with a 9-year history of ovarian cancer: is exposure to pegylated liposomal Doxorubicin a factor?Giovanni Randon, M Ornella Nicoletto, Nicola Milite, et al.
Molecular Cancer Therapeutics|November 11, 2011
Bortezomib: understanding the mechanism of actionBilal Piperdi, Yi-He Ling, Leonard Liebes, et al.
The Oncologist|February 25, 2014
Continuous-infusion topotecan and erlotinib: a study in topotecan-pretreated ovarian cancer assessing shed collagen epitopes as a marker of invasivenessEiran Warner, Leonard Liebes, Benjamin Levinson, et al.
Breast Care (Basel, Switzerland)|November 7, 2018
Meeting Report: Hereditary Breast and Ovarian Cancer (HBOC): Risks and Challenges. September 10-12, 2009 Bari, ItalyAngelo Paradiso, Stefania Tommasi, Brunella Pilato, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancerHoward Hochster, Abraham Chachoua, James Speyer, et al.
Kidney International|January 2, 2014
Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancerLinda Shavit, Meyer D Lifschitz, Alberto Gabizon, et al.
Anticancer Research|March 9, 2012
Cisplatin with capecitabine: tolerance and activity in a phase I/II study preferentially enrolling patients with gastric cancerJennifer Wu, Theresa Ryan, Benjamin Levinson, et al.
Ecancermedicalscience|September 1, 2020
Endometrial adenocarcinoma presenting as a suprasellar mass: lessons to be learnedEvgenia Granina, Julia Fehniger, Douglas Kondziolka, et al.
Gynecologic Oncology Reports|October 21, 2020
Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinomaAndrey Moiseyenko, Franco Muggia, Thomas Condamine, et al.
Annals of Surgical Oncology|October 2, 2013
Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatinMaryann Kwa, Susan Edwards, Andrea Downey, et al.
Pageof 10